Remko Milan, Swart Marcel, Bickelhaupt F Matthias
Comenius University, Department of Pharmaceutical Chemistry, Odbojarov 10, SK-832 32 Bratislava, Slovakia.
Bioorg Med Chem. 2006 Mar 15;14(6):1715-28. doi: 10.1016/j.bmc.2005.10.020. Epub 2005 Nov 2.
The methods of theoretical chemistry have been used to elucidate the molecular properties of the substituted imidazoline and oxazoline structures, a class of potent agonists and antagonists of imidazoline receptors. The geometries of various tautomers and isomers of 2-[2,6-dichlorophenylimino]imidazolidine (clonidine), 1-(N-dicyclopropylmethyl)amino-2-oxazoline (rilmenidine), 4-chloro-N-(4,5-dihydro-1H-imidazol-2yl)-6-methoxy-2-methyl-5-pyrimidinamine (moxonidine), N-(dicyclopropylmethyl)-4,5-dihydro-1H-pyrrol-2-amine (aminopyrroline), N-dicyclopropylmethyl-4,5-dihydrothiazol-2-amine (aminothiazoline), 4,5-dihydro-2-(2-methoxyphenyl)-1H-imidazole (compound_6), 4,5-dihydro-2-(3-methylthiophen-2-yl)-1H-imidazole (compound_7), N-(2-chloro-4-iodophenyl)-4,5-dihydro-5-methyl-3H-pyrrol-2-amine (LNP_911), N-amidino-3,5-diamino-6-chloropyrazine-carboxamide (amiloride), 2-(1,4-benzodioxan-2-yl)-2-imidazoline (idazoxan), (+/-)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline (efaroxan), (4-aminobutyl)guaninine (agmatine), and 1-methyl-9H-pyrido[3,4-b]indole (harmane) have been studied using Becke3LYP/6-31+G(d,p) and BP86/TZ2P DFT methods. The optimized geometries indicate that these molecules show a distinctly nonplanar configuration of the imidazoline and oxazoline moieties. In the gas-phase, rilmenidine and aminothiazoline exist in two forms (amino and imino), the amino tautomers being more stable by about 6 kJ/mol. The calculations showed, in agreement with experiments, that clonidine, moxonidine, and LNP_911 exist in a more stable imino tautomer. The tautomer containing the amino group is by about 30 kJ/mol less stable. Computations that include the effect of solvation indicated that also in water the relative stability order of individual tautomers (amino and imino forms) is preserved. The computed pKa values varied between 6.7 and 9.0, and correlate well with the available experimental pKa's found in the literature. Among the clinically useful antihypertensives moxonidine exhibits the lowest basicity in water. At pH = 7.4 only about 50% of this drug exists in ionized form. The available experimental partition coefficients of compounds investigated are best reproduced by the CLOGP method. The computed partition coefficients varied between -1.80 (agmatine) and 5.35 (LNP_911) (CLOGP). Clonidine, moxonidine, and rilmenidine are moderately lipophilic compounds with lipophilicities between these two extreme values. The computed solubilities (about 0.1-4 g/L) show that the imidazoline and oxazoline derivatives studied have very low water solubility. The analysis of molecular descriptors defined by Lipinski has shown that most of the compounds studied obey 'rule of five'. Amiloride and agmatine 'outlets' exhibit also the lowest absorption. Therefore, in the early stages of the design of ligands acting on imidazoline binding sites, it is becoming more important to determine the pKa, lipophilicity, water solubility, polar surface area, absorption, and other physicochemical properties associated with a drug, before synthetic work is undertaken, with the aim of avoiding the synthesis of compounds that are predicted to have poor biopharmaceutical characteristics.
理论化学方法已被用于阐明取代咪唑啉和恶唑啉结构的分子性质,这是一类咪唑啉受体的强效激动剂和拮抗剂。使用Becke3LYP/6 - 31 + G(d,p)和BP86/TZ2P密度泛函理论(DFT)方法研究了2 - [2,6 - 二氯苯基亚氨基]咪唑烷(可乐定)、1 - (N - 二环丙基甲基)氨基 - 2 - 恶唑啉(利美尼定)、4 - 氯 - N - (4,5 - 二氢 - 1H - 咪唑 - 2 - 基)-6 - 甲氧基 - 2 - 甲基 - 5 - 嘧啶胺(莫索尼定)、N - (二环丙基甲基)-4,5 - 二氢 - 1H - 吡咯 - 2 - 胺(氨基吡咯啉)、N - 二环丙基甲基 - 4,5 - 二氢噻唑 - 2 - 胺(氨基噻唑啉)、4,5 - 二氢 - 2 - (2 - 甲氧基苯基)-1H - 咪唑(化合物_6)、4,5 - 二氢 - 2 - (3 - 甲基噻吩 - 2 - 基)-1H - 咪唑(化合物_7)、N - (2 - 氯 - 4 - 碘苯基)-4,5 - 二氢 - 5 - 甲基 - 3H - 吡咯 - 2 - 胺(LNP_911)、N - 脒基 - 3,5 - 二氨基 - 6 - 氯吡嗪 - 甲酰胺(阿米洛利)、2 - (1,4 - 苯并二恶烷 - 2 - 基)-2 - 咪唑啉(伊达唑胺)、(±)-2 - (2 - 乙基 - 2,3 - 二氢 - 2 - 苯并呋喃基)-2 - 咪唑啉(依发罗新)、(4 - 氨基丁基)胍(胍丁胺)和1 - 甲基 - 9H - 吡啶并[3,4 - b]吲哚(哈尔满)的各种互变异构体和异构体的几何结构。优化后的几何结构表明,这些分子的咪唑啉和恶唑啉部分呈现出明显的非平面构型。在气相中,利美尼定和氨基噻唑啉以两种形式(氨基和亚氨基)存在,氨基互变异构体更稳定,大约稳定6 kJ/mol。计算结果与实验一致,表明可乐定、莫索尼定和LNP_911以更稳定的亚氨基互变异构体形式存在。含氨基的互变异构体稳定性低约30 kJ/mol。包含溶剂化效应的计算表明,在水中各互变异构体(氨基和亚氨基形式)的相对稳定性顺序也得以保留。计算得到的pKa值在6.7至9.0之间,与文献中可用的实验pKa值相关性良好。在临床有用的抗高血压药物中,莫索尼定在水中的碱性最低。在pH = 7.4时,该药物仅约50%以离子形式存在。所研究化合物的可用实验分配系数通过CLOGP方法能得到最佳重现。计算得到的分配系数在 - 1.80(胍丁胺)至5.35(LNP_911)(CLOGP)之间变化。可乐定、莫索尼定和利美尼定是中等亲脂性化合物,亲脂性介于这两个极值之间。计算得到的溶解度(约0.1 - 4 g/L)表明,所研究的咪唑啉和恶唑啉衍生物的水溶性非常低。对由Lipinski定义的分子描述符的分析表明,所研究的大多数化合物遵循“五规则”。阿米洛利和胍丁胺“例外”,其吸收也最低。因此,在设计作用于咪唑啉结合位点的配体的早期阶段,在进行合成工作之前确定与药物相关的pKa、亲脂性、水溶性、极性表面积、吸收及其他物理化学性质变得越发重要,目的是避免合成预计具有不良生物药剂学特性的化合物。